Actively Recruiting
Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure
Led by University Hospital, Montpellier · Updated on 2025-09-30
710
Participants Needed
12
Research Sites
296 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Montpellier
Lead Sponsor
E
EURO BIO Scientific
Collaborating Sponsor
AI-Summary
What this Trial Is About
Management of patients with heart Failure remains a major health concern because of the high rate of rehospitalization, mortality and induced-cost. Biomarkers could help to guide the management of patients with heart failure (HF). Soluble suppression of tumorigenicity 2 (sST2) appears as a promising biomarker. As a working hypothesis, we postulate that sST2 values monitoring could be an helpful guide for medical management in an attempt to reduce hospital readmission.
CONDITIONS
Official Title
Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older
- Hospitalization for heart failure with NTproBNP ≥450 pg/ml or BNP ≥400 pg/ml
You will not qualify if you...
- Waiting for heart transplantation
- Scheduled valve surgery
- Not fluent in French
- Unable to provide informed consent
- Hemodynamic instability
- Poor outcome during the first week
- Pregnancy
- Participating in another study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Lapeyronie Hospital
Montpellier, Occitanie, France, 34295
Active, Not Recruiting
2
CHU Angers
Angers, France
Actively Recruiting
3
CHU Besançon
Besançon, France
Actively Recruiting
4
CH Béziers
Béziers, France
Actively Recruiting
5
CHU Caen
Caen, France
Actively Recruiting
6
CHU Grenoble
Grenoble, France
Actively Recruiting
7
Arnaud de Villeneuve Hospital
Montpellier, France
Actively Recruiting
8
CHU Nimes
Nîmes, France
Actively Recruiting
9
APHP Pompidou
Paris, France
Not Yet Recruiting
10
CHU Rennes
Rennes, France
Not Yet Recruiting
11
CHU Toulouse
Toulouse, France
Actively Recruiting
12
CHU Vannes
Vannes, France
Actively Recruiting
Research Team
J
Jean-Paul CRISTOL, MD, PhD
CONTACT
A
Anne-Marie GORCE DUPUY
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here